ArticleMedical journal of the Islamic Republic of Iran2026
Practical Application of Remdesivir-Based Regimens in COVID-19: A Retrospective Case-Control Analysis.
Article in Medical journal of the Islamic Republic of Iran, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The SARS-CoV-2 pandemic strained global healthcare, creating a demand for effective inpatient treatments. Observational comparisons of remdesivir (RDV) versus non-RDV are subject to confounding by indication and temporal trends. This study assessed the real-world effectiveness of RDV-based regimens using propensity score matching (PSM). Methods: We conducted a single-center retrospective cohort study at BouAli Hospital, analyzing 2,216 adults hospitalized with COVID-19 between March and September 2020. The propensity score for RDV receipt was estimated via logistic regression including age, admission SpO₂, comorbidities, vaccination status, adjunct therapies, and pandemic wave. Patients were matched 1:1 by nearest neighbor (caliper 0.2 SD, common support). Covariate balance was assessed using standardized mean differences (SMD). Outcomes included hospital mortality, ICU admission, intubation, and length of stay (LOS). Results: PSM produced 1,108 well-matched pairs (n=2,216). Some imbalance persisted (largest |SMD|: atorvastatin 0.35; vaccination 0.35; wave 0.24; age 0.17). RDV was associated with a lower intubation risk (OR 0.50, 95% CI 0.39-0.65; Conclusion: After PSM and adjustment, RDV use was linked to reduced intubation but not ICU admission or mortality, with longer hospital stays observed. Residual imbalance and unmeasured severity limit causal inference. Further studies are needed to guide personalized COVID-19 treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.